MedWatch

Expensive biomedicine sets the agenda

The number of biological drugs under clinical development in Denmark has increased rapidly in later years, as have government expenses for biomedicine.

Biotech companies all over the world are focusing more and more on the development of biological drugs, rather than chemical ones, and the tendency is seen in Denmark as well.

In 2010 about a third of the Danish drugs in clinical development were biological, according to a report compiled by the consultancy firm Damvad on behalf of The Danish Association of the Pharmaceutical Industry.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier